Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease (ExpeditionPRO)

25 de setembro de 2019 atualizado por: Eli Lilly and Company

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).

Visão geral do estudo

Status

Rescindido

Condições

Tipo de estudo

Intervencional

Inscrição (Real)

26

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Chemnitz, Alemanha, 09131
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Gatineau, Canadá, J8T 8J1
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Greenfield Park, Canadá, J4V 2J2
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Halifax, Canadá, B3S1M7
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Kentville, Canadá, B4N 4K9
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • London, Canadá, N6C 0A7
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Ottawa, Canadá, KIN 5C8
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Peterborough, Canadá, K9H2P4
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Sherbrooke, Canadá, J1H1Z1
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Toronto, Canadá, M3B 2S7
        • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
      • Barcelona, Espanha, 08025
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Barcelona, Espanha, 08036
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Barcelona, Espanha, 08014
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Castellon de la Plana, Espanha, 12004
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Getafe, Espanha, 28905
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Getxo, Espanha, 48993
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Madrid, Espanha, 28006
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Plasencia, Espanha, 10600
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Salt, Espanha, 17190
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • San Sebastian, Espanha, 20009
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Valencia, Espanha, 46017
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Valencia, Espanha, 46026
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85006
        • Banner Alzheimer's Institute
      • Phoenix, Arizona, Estados Unidos, 85013
        • St Josephs Hospital and Medical Center
      • Phoenix, Arizona, Estados Unidos, 85004
        • Xenoscience
      • Sun City, Arizona, Estados Unidos, 85351
        • Banner Sun Health Research Institute
      • Tucson, Arizona, Estados Unidos, 85718
        • Center For Neurosciences
      • Tucson, Arizona, Estados Unidos, 85724
        • Arizona Health Sciences Center
    • California
      • Glendale, California, Estados Unidos, 91206-4140
        • Parexel Early Phase Unit at Glendale
      • Oxnard, California, Estados Unidos, 93030
        • Pacific Neuroscience Medical Group
      • Rancho Mirage, California, Estados Unidos, 92270
        • Desert Valley Research
      • San Diego, California, Estados Unidos, 92123
        • Sharp Mesa Vista Hospital
      • San Diego, California, Estados Unidos, 92103
        • Pacific Research Network Inc
      • San Francisco, California, Estados Unidos, 94114
        • California Pacific Medical Center
      • Santa Ana, California, Estados Unidos, 92705
        • Apex Research Institute
      • Santa Clarita, California, Estados Unidos, 91321
        • Care Access Research LLC
      • Sherman Oaks, California, Estados Unidos, 91403
        • California Neuroscience Research
      • Valencia, California, Estados Unidos, 91355
        • Care Access Research
    • Colorado
      • Colorado Springs, Colorado, Estados Unidos, 80910
        • MCB Clinical Research Centers
      • Denver, Colorado, Estados Unidos, 80218
        • Mile High Research Center
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Yale University School of Medicine
      • Stamford, Connecticut, Estados Unidos, 06905
        • New England Institute for Clinical Research
    • Delaware
      • Newark, Delaware, Estados Unidos, 19713
        • Christiana Care Research Institute
    • Florida
      • Delray Beach, Florida, Estados Unidos, 33445
        • Brain Matters Research
      • Fort Myers, Florida, Estados Unidos, 33912
        • Neuropsychiatric Research Center of Southwest Florida
      • Hollywood, Florida, Estados Unidos, 33021
        • Sunrise Clinical Research
      • Jacksonville, Florida, Estados Unidos, 32256
        • Clinical Neuroscience Solutions Inc
      • Miami, Florida, Estados Unidos, 33137
        • Miami Jewish Health Systems
      • Miami Beach, Florida, Estados Unidos, 33140
        • Mount Sinai Medical Center
      • New Port Richey, Florida, Estados Unidos, 34652
        • Suncoast Clinical Research
      • Ocoee, Florida, Estados Unidos, 34761
        • Sensible Healthcare
      • Orlando, Florida, Estados Unidos, 32806
        • Compass Research
      • Pensacola, Florida, Estados Unidos, 32502
        • Pensacola Research Consultants, Inc.
      • Pompano Beach, Florida, Estados Unidos, 33064
        • Quantum Laboratories
      • Sarasota, Florida, Estados Unidos, 34243
        • Roskamp Institute
      • Tampa, Florida, Estados Unidos, 33609
        • Axiom Research
      • West Palm Beach, Florida, Estados Unidos, 33407
        • Premiere Research Institute at Palm Beach Neurology
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30331
        • Atlanta Center of Medical Research
      • Gainesville, Georgia, Estados Unidos, 30501
        • United Osteoporosis Center
    • Illinois
      • Champaign, Illinois, Estados Unidos, 61820
        • Christie Clinic, LLC
      • Elk Grove Village, Illinois, Estados Unidos, 60007
        • Alexian Brothers Medical Center
      • Winfield, Illinois, Estados Unidos, 60190
        • Central DuPage Hospital
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46804
        • Fort Wayne Neurological Center
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University School of Medicine
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Josephson Wallack Munshower Neurology
    • Kansas
      • Topeka, Kansas, Estados Unidos, 66606
        • Cotton O'Neil Clinic
      • Wichita, Kansas, Estados Unidos, 67207
        • Heartland Research Associates
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40503
        • Baptist Health Medical Group
    • Louisiana
      • Lake Charles, Louisiana, Estados Unidos, 70629
        • Lake Charles Clinical Trials
    • Maine
      • Scarborough, Maine, Estados Unidos, 04074
        • Maine Neurology
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21285
        • Sheppard Pratt Health System
      • Baltimore, Maryland, Estados Unidos, 21204
        • Sheppard Pratt Health System
      • Baltimore, Maryland, Estados Unidos, 21205
        • Johns Hopkins University School of Medicine
      • Baltimore, Maryland, Estados Unidos, 21208
        • Pharmasite Research Inc
    • Massachusetts
      • Methuen, Massachusetts, Estados Unidos, 01844
        • ActivMed Practices & Research, Inc
      • Plymouth, Massachusetts, Estados Unidos, 02360-4843
        • Donald S Marks
    • Michigan
      • Farmington Hills, Michigan, Estados Unidos, 48334
        • Quest Research Institute
    • Mississippi
      • Hattiesburg, Mississippi, Estados Unidos, 39401
        • Hattiesburg Clinic
    • Missouri
      • Bolivar, Missouri, Estados Unidos, 65613
        • Clinvest
      • Chesterfield, Missouri, Estados Unidos, 63141
        • Clinical Research Professionals
      • Creve Coeur, Missouri, Estados Unidos, 63141
        • Millenium Psychiatric Associates LLC
      • Kansas City, Missouri, Estados Unidos, 64111
        • St Lukes Hospital
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89113
        • Las Vegas Medical Research
    • New Hampshire
      • Nashua, New Hampshire, Estados Unidos, 03060
        • Healthy Perspectives Innovative Mental Health Services, PL
      • Portsmouth, New Hampshire, Estados Unidos, 03801
        • ActivMed Practices & Research, Inc
    • New Jersey
      • Eatontown, New Jersey, Estados Unidos, 07724
        • Memory Enhancement Center of America, Inc.
      • Monroe, New Jersey, Estados Unidos, 08831
        • Pyramid Clinical Research
      • Princeton, New Jersey, Estados Unidos, 08540
        • Princeton Medical Institute
      • Springfield, New Jersey, Estados Unidos, 07081
        • The Cognitive and Research Center of NJ
      • Toms River, New Jersey, Estados Unidos, 08755
        • Advanced Memory Research Institute of New Jersey
      • Toms River, New Jersey, Estados Unidos, 08755
        • Bio Behavioral Health
    • New York
      • Albany, New York, Estados Unidos, 12206
        • Albany Medical College
      • Staten Island, New York, Estados Unidos, 10312
        • Richmond Behavorial Associates
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28270
        • Alzheimer's Memory Center
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Piedmont Medical Research
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • University of Cincinnati Medical Center
      • Dayton, Ohio, Estados Unidos, 45459
        • Neurology Diagnostics, Inc.
      • Shaker Heights, Ohio, Estados Unidos, 44122
        • Insight Clinical Trials
    • Oregon
      • Portland, Oregon, Estados Unidos, 97225
        • Center for Cognitive Health
      • Portland, Oregon, Estados Unidos, 97210
        • Summit Research Network Inc
    • Pennsylvania
      • Abington, Pennsylvania, Estados Unidos, 19090
        • Abington Neurological Associates
      • Allentown, Pennsylvania, Estados Unidos, 18104
        • Lehigh Center For Clinical Research
      • Allentown, Pennsylvania, Estados Unidos, 18103
        • Lehigh Valley Hospital
      • Jenkintown, Pennsylvania, Estados Unidos, 19046
        • Clinical Trial Center, LLC, Psychiatry
      • Plains, Pennsylvania, Estados Unidos, 18705
        • Northeastern Pennsylvania Memory & Alzheimer's Center
    • Rhode Island
      • East Providence, Rhode Island, Estados Unidos, 02914
        • Rhode Island Mood & Memory Research Institute
      • Providence, Rhode Island, Estados Unidos, 02906
        • Butler Hospital
    • South Carolina
      • Indian Land, South Carolina, Estados Unidos, 29707
        • Metrolina Neurological Research Institute
    • Texas
      • Dallas, Texas, Estados Unidos, 75231
        • FutureSearch Trials
      • Dallas, Texas, Estados Unidos, 75231
        • Baylor AT&T Memory Center
      • Dallas, Texas, Estados Unidos, 75219
        • Baylor AT&T Memory Center
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist
      • Houston, Texas, Estados Unidos, 77054
        • University of Texas Health Services Center - Houston
      • San Antonio, Texas, Estados Unidos, 78229
        • Clinical Trials of Texas, Inc.
      • San Antonio, Texas, Estados Unidos, 78229
        • Univ of Texas Health Science Center at San Antonio
    • Vermont
      • Bennington, Vermont, Estados Unidos, 05201
        • The Memory Clinic
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23510
        • Sentara Medical Group
      • Richmond, Virginia, Estados Unidos, 23294
        • National Clinical Research - Richmond
    • Washington
      • Kirkland, Washington, Estados Unidos, 98034
        • Evergreen Professional Plaza
    • Wisconsin
      • Middleton, Wisconsin, Estados Unidos, 53562
        • Dean Foundation for Health Research and Education
      • Kuopio, Finlândia, 70210
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Oulu, Finlândia, 90100
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tampere, Finlândia, 33100
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Turku, Finlândia, 20014
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Vaasa, Finlândia, 65130
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Amiens, França, 80054
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bordeaux, França, 33076
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bron, França, 69677
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lille, França, 59037
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Marseille, França, 13385
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Montpellier, França, 34295
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Paris, França, 75015
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Paris, França, 75651
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Paris, França, 75010
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Rennes, França, 35033
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Strasbourg, França, 67000
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Toulouse, França, 31059
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Genova, Itália, 16132
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Milano, Itália, 20122
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Milano, Itália, 20133
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Monza, Itália, 20052
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Pavia, Itália, 27100
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Perugia, Itália, 06134
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Pisa, Itália, 56126
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Roma, Itália, 00161
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Roma, Itália, 00153
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Roma, Itália, 00179
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Roma, Itália, 00189
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bunkyo-ku, Japão, 113-8655
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bunkyo-ku, Japão, 113-8431
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Hachioji, Japão, 193-0998
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Hyogo, Japão, 673-0848
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kamakura, Japão, 247-8533
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kodaira-shi, Japão, 187-8551
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Koriyama, Japão, 963-8052
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kyoto-shi, Japão, 607-8113
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Mitaka-shi, Japão, 181-0013
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Shinjuku-Ku, Japão, 160-8582
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Shizuoka, Japão, 424-0911
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Takamatsu, Japão, 760-8557
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tokyo, Japão, 113-0034
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tsu-shi, Japão, 514-8507
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Białystok, Polônia, 15-732
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bydgoszcz, Polônia, 85-796
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Lublin, Polônia, 20-093
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Poznan, Polônia, 30-856
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Sopot, Polônia, 81-824
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Warszawa, Polônia, 01-697
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Bayamón, Porto Rico, 00961-6911
        • Santa Cruz Behavioral PSC
      • Las Piedras, Porto Rico, 00771
        • Cortex, PSC
      • Rio Piedras, Porto Rico, 00936
        • University of Puerto Rico
      • San Juan, Porto Rico, 00918
        • Instituto De Neurologia Dra. Ivonne Fraga
      • San Juan, Porto Rico, 00918
        • SomniCare Sleep Institute
      • San Juan, Porto Rico, 00918
        • Latin Clinical Trial Center
      • Bath, Reino Unido, BA1 3NG
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Chelsea, Reino Unido, W6 8RF
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Guildford, Reino Unido, GU2 7YD
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • London, Reino Unido, W1G 9RU
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Manchester, Reino Unido, M13 9WL
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Scotland, Reino Unido, G20 0XA
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Malmö, Suécia, 20502
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Mölndal, Suécia, 43141
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Stockholm, Suécia, 113 61
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Umeå, Suécia, 90105
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Changhua, Taiwan, 500
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Gwei Shan Township, Taiwan, 333
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Jhonghe City, Taiwan, 235
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kaohsiung, Taiwan, 80756
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Kaohsiung, Taiwan, 83301
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Taichung, Taiwan, 40447
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Tainan, Taiwan, 70403
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Taipei, Taiwan, 10048
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
      • Taipei, Taiwan, 11217
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

55 anos a 85 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Has a diagnosis by the study investigator of a clinical syndrome of cognitive impairment consistent with prodromal AD per International Working Group (IWG) diagnostic criteria or mild cognitive impairment (MCI) due to AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.
  • Scores 17-28 on Montreal Cognitive Assessment (MoCA) at screening.
  • Scores <27 on free recall cutoff score from the Free and Cued Selective Reminding Test (FCSRT) (Picture version) at screening.
  • Scores ≤4 on Modified Hachinski Ischemia Scale (MHIS).
  • Scores >0 on the Functional Activities Questionnaire (FAQ).
  • Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result at screening consistent with the presence of amyloid pathology.

Exclusion Criteria:

  • Has had MRI or computerized tomography (CT) of brain within previous 2 years showing pathology that would be inconsistent with a diagnosis of AD.
  • Has known allergy to humanized monoclonal antibodies.
  • Has an ongoing clinically significant laboratory abnormality, as determined by the investigator.
  • Has screening MRI with results showing >4 amyloid related imaging abnormalities H (ARIA-H) micro-hemorrhages or presence of ARIA-E.
  • Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.
  • Has received treatment with a stable dose of an acetylcholinesterase (AChEI) inhibitor or memantine for less than 2 months before randomization. (If a participant has recently stopped AChEIs and/or memantine, he or she must have discontinued treatment at least 2 months before randomization.)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Solanezumab
Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
Administrado IV
Outros nomes:
  • LY2062430
Experimental: Placebo
Placebo given IV once every 4 weeks for up to 2 years.
Administrado IV

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog14) Score
Prazo: Baseline, 24 Months
ADAS-Cog14 is ADAS-Cog11 augmented with orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze-completion measures. The ADAS-Cog14 scale ranges from 0 to 90. Higher scores indicate greater disease severity.
Baseline, 24 Months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline on Alzheimer´s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL)
Prazo: Baseline, 24 Months
The ADCS-MCI-ADL is a functional evaluation scale for MCI patients, based on information provided by an informant that describes the performance of participants in several ADLs. Total score ranges from 0 to 69; lower score indicates greater disease severity.
Baseline, 24 Months
Change From Baseline on the Mini Mental Status Examination (MMSE)
Prazo: Baseline, 24 Months
MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants.Total score ranges from 0 to 30; lower score indicates greater disease severity.
Baseline, 24 Months
Change From Baseline on the Montreal Cognitive Assessment (MoCA)
Prazo: Baseline, 24 Months
The MoCA will be used as the global cognitive screening instrument. It will also be administered in the clinical trial at baseline and the final visits of each phase as a secondary outcome measure of global cognition. Scores on the MoCA range from 0-30 with 26-30 indicating normal global cognition.
Baseline, 24 Months
Change From Baseline on the Functional Activities Questionnaire (FAQ)
Prazo: Baseline, 24 Months
FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant's ability to perform a variety of activities ranging from Writing checks, Assembling tax records, shopping, playing games, food preparation, traveling, keeping appointments, Traveling out of neighborhood, keeping track of current events and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. Each activity is rated on a scale from 0 to 3 (Never did and would have difficulty now = 1; Never did [the activity] but could do now = 0; Normal = 0; Has difficulty but does by self = 1; Requires assistance = 2; Dependent = 3). The maximum FAQ total score is 30, with higher scores indicating greater impairment.
Baseline, 24 Months
Change From Baseline on the Neuropsychiatric Inventory (NPI)
Prazo: Baseline, 24 Months
The NPI is a tool for assessing psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. The score ranges from 12 to 144, with higher scores indicating greater disease severity.
Baseline, 24 Months
Change From Baseline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
Prazo: Baseline, 24 Months
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.
Baseline, 24 Months
Change From Baseline on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Prazo: Baseline, 24 Months
RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial/constructional skills.
Baseline, 24 Months
Change From Baseline on the Free and Cued Selective Reminding Test (FCSRT)
Prazo: Baseline, 24 Months
The FCSRT is a neuropsychological test of memory under conditions that control attention and cognitive processing in order to obtain an assessment of memory unconfounded by normal age-related changes in cognition.
Baseline, 24 Months
Change From Baseline on the Resource Utilization in Dementia-Lite (RUD-Lite)
Prazo: Baseline, 24 Months
RUD-Lite assesses the healthcare resource utilization of participants and their caregivers to determine the level of formal and informal care attributable to Alzheimer's Disease (AD). Information on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) is collected from the baseline and follow-up interviews.
Baseline, 24 Months
Change From Baseline on the EuroQol 5-Dimensional Health-Related Quality of Life Scale (EQ-5D)
Prazo: Baseline, 24 Months
EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Visual analogue scale (VAS) assesses caregiver's impression of participant's overall health state; scores range: 0 to 100. Lower scores indicate greater disease severity.
Baseline, 24 Months
Change From Baseline on the Quality of Life in Alzheimer's Disease Scale (QoL-AD)
Prazo: Baseline, 24 Months
QoL for AD assess participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items rated on a 4-point scale. Sum of items=total score (range: 13-52). Higher scores=greater QoL.
Baseline, 24 Months
Change From Baseline in Concentration of Plasma Amyloid-β Peptide (Aβ) and Plasma Solanezumab
Prazo: Baseline, 24 Months
Concentration of amino acid peptide known as Aβ 1-42 in plasma.
Baseline, 24 Months
Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)
Prazo: Baseline, 24 Months
MRI will be used to assess the effect of treatment on rate of whole brain volume.
Baseline, 24 Months
Change From Baseline in Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)
Prazo: Baseline, 24 Months
Florbetapir F18 PET used to assess the treatment effect in brain amyloid plaque deposition from baseline through 18 months as measured by florbetapir F18 PET Standardized Uptake Uptake Value ratio.
Baseline, 24 Months
Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Aβ and CSF Tau Proteins
Prazo: Baseline, 24 Months
Changes in CSF parameters, including total and free Aβ1-40 and Aβ1-42 species and total tau and P-tau181 peptides, will be assessed.
Baseline, 24 Months
Change From Baseline in Neocortical Tau Deposits Using 18F-AV-1451 PET
Prazo: Baseline, 24 Months
Biomarker change will be analyzed to provide biomarker-based evidence that solanezumab affects the underlying disease pathology.
Baseline, 24 Months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de junho de 2016

Conclusão Primária (Real)

1 de maio de 2017

Conclusão do estudo (Real)

1 de maio de 2017

Datas de inscrição no estudo

Enviado pela primeira vez

2 de maio de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de maio de 2016

Primeira postagem (Estimativa)

3 de maio de 2016

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de outubro de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de setembro de 2019

Última verificação

1 de setembro de 2019

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 16349
  • H8A-MC-LZBE (Outro identificador: Eli Lilly and Company)
  • 2016-000108-27 (Número EudraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Prazo de Compartilhamento de IPD

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Critérios de acesso de compartilhamento IPD

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever